A newly published study in Nature Metabolism reports that brown fat can act as a hub of molecular messaging, using secreted microRNAs to coordinate physiology across the body. Researchers focused on brown adipose tissue—well known for its role in thermogenesis—and asked whether it also participates in long-distance communication via RNA signals.

To visualize and track these messages, the team employed brown-fat–specific RNA labeling in living systems. This strategy allowed them to connect RNA production within adipocytes to downstream effects elsewhere, moving beyond correlations toward a clearer map of inter-organ RNA traffic.

The central finding is the presence of a communication network mediated by microRNAs released from brown fat. These small regulatory RNAs appear to travel beyond the tissue of origin and engage gene-regulatory pathways in other organs, effectively relaying information about metabolic state.

Functionally, the work supports a model in which microRNA “dispatch” from thermogenic fat tunes cellular programs in remote targets. Such programs likely involve post-transcriptional regulation, a process microRNAs are known to influence by pairing with complementary sequences in messenger RNAs.

Importantly, the approach does not treat microRNAs as generic circulating molecules. Instead, the labeling confirms their brown-fat origin and strengthens the link between secretory RNA dynamics and systemic physiological outcomes.

The study also highlights the specificity of the messaging: not all RNAs are equally represented, and the labeled microRNA repertoire points to organized, tissue-defined signaling rather than random leakage.

Beyond mapping pathways, the results carry implications for metabolic disease research. If brown fat microRNAs can reshape gene expression in other organs, manipulating these signals could offer a route to modulate energy balance, insulin sensitivity, or inflammatory tone.

For now, the findings provide a blueprint for how RNA labelling combined with tissue specificity can uncover hidden layers of endocrine-like communication. As techniques improve, the field may move toward a broader “RNA connectome” linking organ behavior through secreted regulatory molecules.

Researchers describe their results as evidence that brown fat is not only a metabolic engine but also an information broadcaster. In the evolving landscape of viral-style science news, this discovery underscores how tiny RNA molecules can orchestrate large-scale biological conversations.

Subject of Research: Inter-organ communication via secreted microRNAs from brown adipose tissue.

Article Title: Brown fat-specific RNA labelling reveals a network of inter-organ communication by secreted microRNAs.

Article References: Lino, M., Palermo-Ruiz, G., Efthymiou, V. et al. Brown fat-specific RNA labelling reveals a network of inter-organ communication by secreted microRNAs. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01558-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-026-01558-0

Naked mole-rats have long puzzled biologists with their striking eusocial structure, where most adults remain reproductively suppressed while a queen controls the colony’s future. Now, a new study identifies a chemical “queen odour” that links social status to endocrine control, revealing a mammalian analogue to insect queen pheromones.

The molecule, termed IPM, is enriched by the queen and acts as the key mediator of reproductive suppression in non-breeding females. When IPM is present, circulating prolactin rises while progesterone is suppressed, locking the colony into a stable reproductive hierarchy characterized by reduced conflict and maintained group cohesion.

Crucially, the team connects this behavioural outcome to the brain. Using multiple approaches—including non-invasive functional ultrasound imaging (fUSI)—they show that IPM provokes strong activation of olfactory neurons and central neural circuits. This provides a neural substrate for how a chemical cue can trigger colony-wide physiological change, rather than relying on social learning or passive association.

The experiments also clarify sensory routing. Ablating olfaction abolishes aggression initiation and lowers prolactin levels, directly tying IPM detection to reproductive suppression. While the findings are consistent with sensing through the main olfactory epithelium, the authors note that the vomeronasal system may still contribute.

Queen removal normally destabilizes colonies, leading to aggression, reproductive competition, prolactin decline, and, in extreme cases, mortality. Yet when IPM is added to queenless bedding, the colony remains stable for months. During this period, fecal progesterone metabolite levels stay low, indicating sustained ovarian quiescence alongside elevated prolactin.

The study also addresses a longstanding paradox: transferring soiled bedding and urine from parent colonies fails to maintain suppression in isolated individuals. The authors propose that IPM’s chemistry helps explain this discrepancy. As a long-chain fatty acid ester with low volatility, IPM may persist within the colony environment but fail to travel effectively over distance or survive transfer pathways that preferentially carry other chemicals.

Comparative work extends beyond naked mole-rats. IPM is detected in breeding females of four additional Fukomys species. Although reproductive suppression mechanisms may differ across species, the presence of a similar queen-linked odorant suggests convergent chemical strategies for managing reproductive skew in eusocial mammals.

Overall, the research reframes reproduction control as a chemosensory-to-endocrine pathway: IPM activates olfactory–hypothalamic signalling, elevating prolactin and inhibiting GnRH release. This “social hormone” model offers a new principle for social evolution—chemical cues can synchronize behaviour and physiology at the scale of an entire mammal colony.

Subject of Research: Reproductive suppression and social hierarchy in eusocial mammals (naked mole-rats and related Fukomys species)

Article Title: A queen odour mediates reproductive suppression in a eusocial mammal

Article References:

Khallaf, M.A., Hart, D.W., Luo, W. et al. A queen odour mediates reproductive suppression in a eusocial mammal.
Nature (2026). https://doi.org/10.1038/s41586-026-10772-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10772-5

Keywords: IPM; queen odour; reproductive suppression; prolactin; GnRH; olfaction; eusociality; functional ultrasound imaging; Fukomys

UK regulator Ofcom launched an investigation into TikTok to assess whether the platform is meeting its obligations under the country’s Online Safety Act to protect children from harmful digital content.

The probe will assess whether the ByteDance-owned platform has implemented effective age assurance systems to determine if a user is underage and prevent children from encountering harmful material online.

Ofcom’s Age Assurance report, published today, suggested that some age inference models including those used by TikTok “may have failed to correctly identify a significant proportion of children”, potentially exposing them to harmful content.

If compliance failures are identified, the watchdog could impose fines of up to £18 million or 10% of the company’s global revenue, whichever is greater. In serious cases, it can also order third parties, including payment providers, advertising services or internet service providers, to withdraw services or block access to the platform in the UK.

A TikTok spokesperson told Reuters the platform “strictly enforces age-appropriate experiences through expert-informed platform rules and advanced age inference technologies, in line with major industry peers”, adding, “we are confident that we meet our Online Safety Act obligations and will work with Ofcom to demonstrate this”.

The probe follows initial findings published by Ofcom in May, which revealed TikTok was the service most frequently cited by children as a source of harmful content. More than half of underage users who recalled seeing harmful content identified TikTok as the source, ahead of YouTube, Instagram, Snapchat and Facebook.

At the time, the regulator found personalised, algorithm-driven content feeds were a key route through which children encountered harmful material online. It added TikTok was “particularly concerning” as it was one of the platforms that had “not committed to any significant changes in response to our specific demands”.

Last month, the UK government laid out plans to impose a sweeping ban on social media access for under-16 users, alongside restrictions on gaming and live-streaming platforms.

The post TikTok in Ofcom crosshairs over child safety appeared first on Mobile World Live.

France’s competition authority assumed control of investigating a proposed purchase and subsequent carve-up of SFR by Iliad Group, Bouygues Telecom and Orange, after the European Commission (EC) referred the element falling under its remit.

In a statement, Autorite de la Concurrence estimated its probe into the three related transactions would take at least 18-months due to the complexity of the cases and markets involved.

When the parties announced the agreement in June, they estimated completion in H2 2027.

Because Orange and Bouygues Telecom generate more than two-thirds of their European Union-wide turnover in France, their agreements automatically fell under the remit of the national authority, but the EC could have looked directly into Iliad’s involvement because it did not meet the same criteria.

However, following an application from the company, the European regulator referred that part to France as well.

Autorite de la Concurrence noted the EC had considered it is “best placed to examine the transaction, in particular in view of its impact on the French market, the experience of the Autorite in the sector concerned and the fact the transaction is linked to two transactions with a national dimension”.

It plans to co-operate with the EC during the review.

The French regulator is already in discussions with Orange and Bouygues Telecom ahead of the pair making formal submissions and is now set to undertake a process with Iliad.

Its probe is set to include stakeholder consultation including consumer protection organisations and other regulators.

The post EC hands SFR deal probe to France appeared first on Mobile World Live.

Google DeepMind CEO Demis Hassabis called for the establishment of a new US-led regulatory framework to govern frontier AI, proposing a self-regulatory structure which could bypass political opposition.

In a post on X, Hassabis warned the breakneck pace of commercial and geopolitical competition is currently outstripping the industry’s understanding of the technology.

He noted the arrival of Artificial General Intelligence (AGI) is likely only a few short years away.

To address looming technical, biological, and cybersecurity risks without stifling innovation, Hassabis proposed creating a new US standards body.

He modelled it after a self-regulatory organisation like the Financial Industry Regulatory Authority (FINRA), rather than a traditional government agency.

The structural choice comes amid heavy resistance to AI regulation from the tech industry and shifting policies from the Trump administration.

The FINRA-style blueprint would be staffed by leading technical experts and open-source representatives but primarily funded by the industry to secure the massive compute resources needed for testing.

TechCrunch reported the proposed system would replace the current, highly criticised ad hoc government reviews previously used for models like Anthropic’s Mythos and OpenAI’s Sol.

Those reviews drew fire from industry onlookers for a distinct lack of technical expertise and opaque decision-making, according to the news outlet.

Under Hassabis’s framework, the independent body would define thresholds to classify models as Frontier-Class. Organisations behind them, dubbed Frontier Labs, would eventually be required to pass the independent assessments to deploy in the US market.

Hassabis stated assessments would check for advanced threats, deception, and guardrail bypass attempts. The standards body could also outsource specific evaluations to a growing ecosystem of independent, third-party AI safety groups.

He argued the approach is designed to keep up with AI’s acceleration, allowing the industry to safely steer toward an era of scientific abundance while addressing the Trump administration’s concern over state-mandated red tape.

The post DeepMind CEO seeks US standards body for frontier AI appeared first on Mobile World Live.

The European Commission (EC) approved €659 million in German state aid to finance four new semiconductor facilities, in line with the bloc’s Chips 2.0 Act.

Europe’s executive arm stated the measures would contribute to strengthening the European Union’s (EU) position and autonomy in the semiconductor value chain by supporting “the construction of first-of-a-kind facilities”.

Germany will provide direct grants of €353 million, €214 million, €74.4 million and €17.9 million, respectively, to build the four semiconductor facilities.

The biggest sum will be invested in Baesweiler in North Rhine-Westphalia, on a site to manufacture silicon carbide epi-wafers. The EC explained this new type of semiconductor is expected to be used in various sectors including automotive, industrial, telecoms and energy, enabling improvements in the manufacturing process.

Positive effect
All beneficiaries of the investments have agreed to ensure the broader impact of the projects have positive effects on the EU semiconductor value chain, and strengthens collaboration with universities and research institutions. They also pledged to fulfil orders on a priority basis, develop specialised training programmes and share project-related profits with Germany.

The EC explained an assessment of the plan indicated the measures would promote development of economic activities by creating capacity in Europe, had limited impact on competition and trade in the EU, and had a positive effect on the region’s semiconductor sector.

It stated the awards are the 15^th to 18^th under its Chips Act 2.0 adopted last month and the original Chips Act.

Under the initiatives, it has provided cumulative aid of around €14.2 billion.

The post EC approves €660M German chip investment plan appeared first on Mobile World Live.

Switzerland’s competition authority launched a preliminary antitrust investigation into Google after it scrapped a search engine selection feature for Swiss users setting up Android devices.

In a statement, the country’s Secretariat of the Competition Commission (COMCO) accused Google of discontinuing the Android Choice Screen feature for users in Switzerland while continuing to offer it in the European Economic Area (EEA).

The screen allows users to select their preferred default search engine during the initial setup of a new Android device.

Swiss users are apparently now presented with Google Search as the default option without being shown the Choice Screen. The watchdog argued this could strengthen the search giant’s position by reducing the visibility of rival providers and “reinforcing barriers to entry” at a critical stage of device setup.

The Choice Screen is designed to reduce “the lock-in effects associated with preconfigured settings”, noting default settings “play a decisive role” in digital markets, the regulator stated.

The watchdog flagged broader competition concerns, stating the change “could affect the ability of search engine providers and, more broadly, other digital service providers to compete”.

A further point of concern for COMCO was the continued availability of the feature in the EEA, arguing the disparity “creates an unequal treatment…even though the competitive issues are comparable”.

Wider assessment
The preliminary investigation will determine whether Google’s conduct breaches Switzerland’s Cartel Act, under which COMCO can impose administrative fines of up to 10% of a company’s Swiss turnover over the previous three years.

“We look forward to cooperating fully with the authority to address ​their questions,” a Google spokesperson told Reuters.

While the probe is focused on Android, the watchdog added its findings “could also be relevant to the assessment of practices related to default settings on other mobile devices”.

Early this year, the UK’s Competition and Markets Authority (CMA) opened a similar antitrust investigation into Google’s mobile ecosystem over concerns the company used its market power to set up barriers against rival services and favour their own products.

The post Google faces Swiss antitrust probe over search defaults appeared first on Mobile World Live.

A groundbreaking study from Mass General Brigham Neuroscience Institute has uncovered crucial genetic underpinnings of congenital cerebral ventriculomegaly (CCV), a disorder characterized by the abnormal swelling of fluid-filled brain ventricles in fetuses. Frequently observed alongside autism spectrum disorder and other neurodevelopmental conditions, CCV has long been a clinical challenge due to its complex origins and unpredictable outcomes.

By analyzing genetic data from approximately 2,700 children diagnosed with CCV and their parents, researchers identified rare, deleterious mutations affecting genes integral to early brain development. These genes regulate the growth and organization of neural cells critical to forming the cerebral cortex—the brain’s center for cognition, memory, and language. Notably, mouse models in which these genes were silenced exhibited enlarged ventricles, linking genetic abnormalities directly to functional and structural brain defects.

This pioneering work shifts the medical understanding of CCV from purely a cerebrospinal fluid circulation disorder to one deeply rooted in developmental brain pathology. It suggests that the ventricular system’s dysfunction reflects a broader impairment in neural circuit formation and brain architecture, potentially explaining why many infants with CCV experience developmental delays and an increased risk of autism.

The implications of these findings are profound. Prenatal neuroimaging combined with targeted genetic screening could enable earlier diagnosis of at-risk fetuses, opening the door to timely interventions before the onset of symptoms. Current neurosurgical treatments, while often lifesaving, do not consistently improve neurological outcomes and expose patients to risks such as infections and lifelong shunt dependency.

Kristopher T. Kahle, MD, PhD, Chief of Pediatric Neurosurgery at Mass General Brigham and senior author of the study, emphasizes the potential of genomic testing to revolutionize patient care. He anticipates that genetic profiling could refine clinical decisions, distinguishing patients who would benefit from surgery from those better served by alternative therapies.

The study’s integration of human genetic analysis with animal modeling represents a paradigm shift, enhancing our grasp of how genetic mutations disrupt cerebrospinal fluid dynamics and cerebral cortex development simultaneously. This dual perspective is poised to stimulate further research aimed at therapeutic innovations targeting the molecular roots of CCV.

Ultimately, this research underscores a critical nexus between developmental neurogenetics and pediatric neurosurgery, offering hope for improved diagnostic precision and personalized treatment strategies. With continued advancements, clinicians may one day prevent or mitigate the neurodevelopmental disabilities often associated with ventriculomegaly, improving quality of life for countless affected children.

Subject of Research: Human tissue samples
Article Title: Developmental genetic determinants of the human cerebrospinal fluid-ventricular system
News Publication Date: —
Web References: https://doi.org/10.1126/scitranslmed.aec4386
References: Allington G et al. Science Translational Medicine. DOI: 10.1126/scitranslmed.aec4386
Keywords: Hydrocephalus, Congenital cerebral ventriculomegaly, Neurodevelopmental disorders, Autism spectrum disorder, Pediatric neurosurgery, Genomic testing

In a groundbreaking fusion of cutting-edge technology and dermatological research, scientists at Biohub have unveiled novel therapeutic targets for psoriasis by conducting the first comprehensive genome-wide CRISPR screen in primary human adult skin cells. By overcoming the longstanding technical hurdle of delivering CRISPR components into notoriously resistant keratinocytes without toxicity, the team utilized centrifuge-based transfection to probe the genetic regulators involved in psoriasis, a chronic inflammatory skin disorder affecting millions globally.

This innovative approach involved knocking out approximately 19,000 genes in keratinocytes sourced from human donors using a vast CRISPR guide RNA library. The focus was on modulating IL17RA, a pivotal receptor that mediates skin inflammation, to chart a genome-wide landscape of genes influencing inflammatory pathways directly in the skin’s outermost layer. The resultant massive data set was then mined using an AI-driven model, VirtualCRISPR, which cross-referenced each gene’s significance against existing scientific literature to highlight previously unrecognized contributors to psoriasis pathology.

Strikingly, this AI-guided screen pinpointed two promising protein targets: ALOX5, an enzyme targeted by the asthma medication zileuton, and OXTR, the gene encoding for the oxytocin receptor, a surprising candidate unassociated before with skin inflammation. Validation experiments in 3D reconstructed human skin cultures demonstrated that zileuton modulates keratinocyte metabolism to suppress inflammation independently from immune cells, revealing a direct pharmacological avenue.

Importantly, topical formulations containing zileuton and cligosiban, an OXTR antagonist, were tested in a mouse model of psoriasis, achieving comparable efficacy to standard injected biologics that broadly suppress immune function. Beyond mitigating inflammation, OXTR inhibition appeared to restore skin barrier integrity—a crucial factor in chronic disease progression—spotlighting this receptor as a novel therapeutic axis.

Unlike current systemic therapies, which often carry risks of broad immunosuppression and high costs, these localized topical interventions promise targeted treatment with minimal systemic exposure. Moreover, the safety profiles of zileuton and OXTR antagonists are well-established in clinical settings, potentially accelerating their repurposing for dermatological applications.

This study exemplifies the transformative power of integrating AI with high-dimensional genetic screening to unravel complex disease mechanisms in cell types previously inaccessible to large-scale functional genomics. By enabling direct investigation into keratinocyte biology, the research not only charts a course for new psoriasis treatments but also sets a precedent for applying similar methodologies to other inflammatory conditions.

As psoriasis affects roughly 125 million people worldwide, innovations enabling precise, effective, and safer therapies could revolutionize patient care. Biohub’s approach heralds a new era where AI-guided CRISPR screens expedite the discovery of unexpected drug targets and foster the development of locally acting, biology-informed treatments.

---

Subject of Research: Psoriasis therapeutic targets via genome-wide CRISPR screening of human skin cells

Article Title: AI-guided CRISPR screening reveals therapeutic targets in psoriasis

News Publication Date: 8-Jul-2026

Web References:
https://www.nature.com/articles/s41467-026-75249-5

References:
DOI: 10.1038/s41467-026-75249-5

Image Credits: Biohub

Keywords

Psoriasis, CRISPR, Oxytocin receptor, ALOX5, Zileuton, Cligosiban, Keratinocytes, AI-guided screening, Inflammation, Topical therapeutics

A groundbreaking study unveils how the ARP2/3 complex orchestrates the dynamic behavior of neurites, providing fresh insights into neuronal growth and polarity. Researchers utilized advanced optogenetic tools to manipulate RAC1, an upstream regulator of ARP2/3, revealing spatially distinct roles of actin assembly in neuronal morphology.

By employing photoactivatable RAC1 (PA-RAC1), the team demonstrated that ARP2/3-mediated actin assembly at neurite tips promotes growth cone activation and neurite extension. Local activation of PA-RAC1 triggered robust growth cone dynamics, driving neurite elongation. Conversely, activation of a dominant-negative RAC1 mutant led to collapse of the growth cone and neurite retraction, underscoring ARP2/3’s role in sustaining neurite advancement.

Intriguingly, PA-RAC1 activation at the soma induced lamellipodia formation reminiscent of nascent actin waves, which were associated with neurite retraction events. This phenomenon mirrored intrinsic cellular behaviors where somatic actin waves correspond with retracting neurites. The study elegantly showed that the emergence of these waves reduced somatic actin patch intensity, indicating a tightly regulated cytoskeletal oscillator mechanism.

The authors further explored the effects of ARP2/3 inhibition using CK-666 perfusion at distinct cellular locales. When applied over the soma and proximal neurites, CK-666 induced neurite retraction, whereas neurites outside this region continued growing unabated. Notably, actin waves were initiated in neurites outside the inhibited zone, propagating retrogradely toward the soma but dissipating upon entering CK-666-exposed areas. This highlights a spatial dependence of ARP2/3 activity for wave initiation and propagation.

Remarkably, simultaneous activation of PA-RAC1 at multiple growth cones revealed competitive dynamics in actin assembly, with enhanced growth cone activity limited to one or two sites. This suggests an intrinsic cellular mechanism balancing cytoskeletal resources and neurite growth across the complex neuronal arborization.

Together, these findings articulate a dual role for ARP2/3: driving actin wave initiation at the soma that triggers neurite retraction, and supporting growth cone expansion at neurite tips to promote extension. This oscillatory interplay mediated by ARP2/3 and RAC1 underscores the cytoskeleton’s fundamental role in establishing neuronal polarity.

This study not only provides a mechanistic framework for how neurons spatially regulate growth and retraction but also suggests that intrinsic cytoskeletal oscillators underpin the dynamic remodeling necessary for proper neuronal circuit formation. These insights pave the way for future investigations into cytoskeletal dysregulation in neurodevelopmental disorders and neuronal regeneration strategies.

The precise spatial control of actin dynamics mediated by ARP2/3 complex activity advances our understanding of neuronal development, highlighting how local cytoskeletal modulators can dictate overall neuronal architecture through oscillatory growth behaviors.

---

Subject of Research: Neuronal cytoskeletal dynamics and polarity establishment

Article Title: An intrinsic cytoskeletal oscillator establishes neuronal polarity

Article References:
Lin, Tc., Coles, C.H., Alfadil, E. et al. An intrinsic cytoskeletal oscillator establishes neuronal polarity. Nature (2026). https://doi.org/10.1038/s41586-026-10755-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10755-6

In a groundbreaking study poised to reshape our understanding of Parkinson’s disease (PD), researchers have unveiled a complex molecular mechanism linking metabolic stress to the disruption of circadian rhythms, with far-reaching implications for neurodegenerative disorders. This deep dive into cellular bioenergetics identifies a glucose-responsive oscillation involving the AMP-activated protein kinase (AMPK), ten-eleven translocation methylcytosine dioxygenase 2 (TET2), and 5-hydroxymethylcytosine (5hmC) axis as a pivotal mediator of metabolic stress responses in the brain. The discovery connects metabolic alterations directly to circadian transcriptional regulation, thereby illuminating previously obscure pathways influencing the onset and progression of Parkinson’s disease.

At the heart of this research lies the energy-sensing enzyme AMPK, a master regulator of cellular metabolism that responds dynamically to changes in cellular energy levels, especially glucose availability. AMPK’s role extends beyond energy balance; it modulates numerous signaling pathways critical for maintaining cellular homeostasis. When glucose levels fluctuate, AMPK activity adjusts accordingly, triggering a cascade of epigenetic modifications mediated by TET2, an enzyme known for its involvement in DNA demethylation and gene expression regulation through oxidative modification of 5-methylcytosine. This AMPK-TET2 interaction sets the stage for rhythmic changes in 5hmC, a key epigenetic mark that fine-tunes circadian gene expression.

The circadian clock is a complex transcriptional network orchestrating daily physiological and behavioral rhythms. Its disruption has been increasingly implicated in neurodegenerative conditions, yet the molecular underpinnings linking metabolism, circadian dysregulation, and neuronal vulnerability have remained elusive. The researchers’ demonstration that metabolic stress-induced AMPK activation regulates TET2-dependent 5hmC oscillations provides a compelling mechanistic bridge. Through this mechanism, energy fluctuations dynamically shape the transcription of circadian genes, potentially disturbing neuronal homeostasis and contributing to PD pathogenesis.

This study utilized a combination of cutting-edge genomic, epigenomic, and proteomic techniques to unravel the dynamics of the AMPK-TET2-5hmC circuit. High-resolution temporal profiling revealed that the oscillations of 5hmC marks at key circadian gene loci are not static but fluctuate in response to metabolic cues. These fluctuations integrate signals of cellular energy status and translate them into rhythmic transcriptional outputs. Importantly, the investigators found that these oscillatory patterns are disrupted in experimental models of Parkinson’s disease, suggesting that the fidelity of metabolic circadian signaling is compromised in neurodegeneration.

A significant aspect of the findings is the direct link between glucose availability and neuronal epigenetic regulation. Metabolic stress, often characterized by reduced glucose uptake or utilization, is a hallmark of aging and neurodegenerative disease states. The AMPK-TET2-5hmC axis serves as a metabolic sensor and effector that translates glucose scarcity into epigenetic reprogramming, thus influencing gene networks that sustain neuronal survival and function. This axis might represent a critical checkpoint where metabolic perturbations exert long-lasting effects on the neuronal epigenome and transcriptome, thereby driving PD progression.

One of the most intriguing revelations of this research is the bidirectional nature of the relationship between metabolic stress and circadian transcription. Not only does metabolic status influence circadian gene expression via epigenetic modulation, but disruptions in circadian regulation feedback to exacerbate metabolic dysfunction. This feedback loop could create a vicious cycle that accelerates neurodegenerative processes, underscoring the importance of maintaining metabolic and circadian integrity for brain health.

The implications of this study extend beyond basic science, offering exciting therapeutic potential. Targeting the AMPK-TET2-5hmC axis may open new avenues for interventions aimed at restoring metabolic and circadian homeostasis in Parkinson’s disease patients. Pharmacological modulators of AMPK activity or epigenetic editors capable of fine-tuning 5hmC dynamics could serve as innovative strategies to halt or slow neurodegeneration. Moreover, optimizing glucose metabolism through lifestyle or pharmacological means might indirectly preserve epigenetic and circadian function, offering a multi-faceted approach to disease management.

The research also highlights the importance of integrating metabolic and epigenetic perspectives to fully capture the complexity of neurodegenerative diseases. Traditional approaches focusing solely on genetic or protein dysfunction have fallen short in explaining the multifactorial etiology and progression of Parkinson’s disease. By illuminating the interplay between energy metabolism and epigenetic regulation, this study sets a new paradigm that could drive future research towards more holistic models of brain pathology.

In addition to elucidating molecular mechanisms, the study provides valuable insights into the temporal dimension of Parkinson’s disease pathology. The rhythmic oscillations of 5hmC marks influenced by glucose and AMPK activity emphasize that timing and metabolic context are crucial factors in disease progression. This may explain the variability in symptom manifestation and disease course among patients and suggests that chronotherapeutic approaches—aligning treatment with the circadian system—could enhance clinical outcomes.

Technologically, the application of multi-omics profiling coupled with advanced computational modeling allowed the researchers to dissect complex regulatory networks with unprecedented precision. Such integrative methodologies are essential for capturing dynamic biological processes that span different molecular layers and timescales. This approach underscores the future direction of biomedical research, where systems biology and temporal dynamics take center stage in unraveling disease mechanisms.

Furthermore, this study draws attention to the overlooked role of 5-hydroxymethylcytosine in the adult brain. Traditionally regarded as mere intermediates in DNA demethylation, 5hmC marks are now recognized as stable epigenetic modifications with distinct regulatory functions. Their oscillatory behavior in response to metabolic cues reveals them as critical mediators linking extracellular environmental factors to nuclear transcriptional machinery, thereby influencing neuronal fate and function.

The association of metabolic stress with circadian dysregulation through the AMPK-TET2-5hmC circuitry also provides a plausible explanation for the observed links between lifestyle factors—such as diet, sleep patterns, and physical activity—and Parkinson’s disease risk. Disruptions in any of these factors can alter glucose metabolism and circadian rhythms, potentially perturbing the delicate balance maintained by this molecular axis and predisposing individuals to neurodegeneration.

Importantly, the study’s findings could redefine biomarker discovery in Parkinson’s disease. Epigenetic oscillations of 5hmC, detectable in neuronal tissues and potentially biofluids, might serve as dynamic indicators of metabolic-circadian health and disease state. This could facilitate earlier diagnosis, tracking of disease progression, and evaluation of therapeutic interventions—ushering in a new era of precision medicine tailored to the metabolic and epigenetic status of patients.

Altogether, the elucidation of the glucose-responsive AMPK-TET2-5hmC oscillation offers a transformative lens through which to understand the intersection of metabolism, epigenetics, and circadian biology in Parkinson’s disease. By identifying a molecular conduit that links metabolic stress to circadian transcriptional misregulation, this research paves the way for innovative diagnostic and therapeutic strategies. As metabolic and circadian dysfunction climb into prominence as central pathogenic drivers, targeted modulation of this axis may hold the key to altering the trajectory of neurodegenerative diseases for millions worldwide.

This pioneering work heralds a new frontier in neuroscience, where cellular energetics, epigenetic remodeling, and circadian rhythms converge to shape neuronal destiny. Understanding and harnessing these complex oscillatory mechanisms offers unprecedented hope for combating the devastating impacts of Parkinson’s disease—a promise that echoes far beyond this single disorder and resonates with the broader quest to unravel the biological rhythms at the core of human health and disease.

---

Subject of Research: The study investigates the molecular mechanism linking metabolic stress, circadian transcriptional regulation, and Parkinson’s disease, focusing on the glucose-responsive AMPK-TET2-5-hydroxymethylcytosine (5hmC) oscillation.

Article Title: Glucose-responsive AMPK-TET2-5hmc oscillation links metabolic stress to circadian transcription and Parkinson’s disease relevance.

Article References: Chu, L., Wang, S., Wang, L. et al. Glucose-responsive AMPK-TET2-5hmc oscillation links metabolic stress to circadian transcription and Parkinson’s disease relevance. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01447-z

Image Credits: AI Generated

The US Federal Communications Commission (FCC) closed an AWS-3 re-auction with gross winning bids topping $3.5 billion in what was the agency’s first spectrum sale after a four-year lapse in activity.

Bidding concluded for Auction 113 yesterday (23 June) after 72 rounds for the 200 licences across the 1695-1710MHz, 1755-1780MHz and 2155-2180MHz bands.

All the licences received bids in the process, which had 17 qualified participants and began on 2 June.

The frequencies were originally auctioned to Dish Network, which is now part of EchoStar, in 2014 but never made it into service after a series of defaults and bid withdrawals left them sitting unused in the FCC’s inventory for more than a decade.

In 2015, Dish Network affiliates Northstar Wireless and SNR Wireless surrendered a number of spectrum licences worth $3.5 billion after a dispute with the FCC over discounts.

In April, the FCC and EchoStar reached an agreement which included the latter dropping a lawsuit it filed in a US Court of Appeals over the defaults by Northstar and SNR.

The financial total carries significant regulatory implications. Up to $3.3 billion of the proceeds will be legally directed to cover funds borrowed for the FCC’s Secure and Trusted Communications Networks Reimbursement Program, commonly known as the “rip and replace” initiative to swap out Huawei and ZTE gear from US networks.

Surpassing the $3.5 billion mark clears the $2.9 billion threshold required for EchoStar to avoid paying a potential shortfall payment to the regulator under a prior settlement framework.

While specific winning bidders remain anonymous under strict anti-collusion quiet period rules, AT&T, Verizon, T-Mobile US and SpaceX are widely expected to have driven the demand.

The event marks a milestone for FCC chair Brendan Carr, representing the return of the agency’s auction power.

“After years on the sidelines, FCC auctions are finally back,” Carr stated. “Today’s successful auction generated billions of dollars in competitive bids to put spectrum to effective commercial use, and it bolsters competition in the wireless marketplace.”

The FCC plans to carry the momentum into its upcoming Upper C-Band auction, tracking on schedule to meet a congressional deadline to auction at least 100MHz of the spectrum by July 2027.

The post FCC wraps AWS-3 re-auction with $3.5B in bids appeared first on Mobile World Live.

Starmer wants to force platforms like YouTube and Facebook to boost BBC content – in spite of the fact that trust in the BBC is collapsing.

The post Starmer Plans to Force Social Media Giants to Prioritise BBC Content appeared first on The Daily Sceptic.

In an era where depression remains one of the most pervasive mental health disorders worldwide, emerging research continues to unravel the complex interactions within our bodies that may offer new treatment avenues. A groundbreaking study recently published in Translational Psychiatry has illuminated a remarkable connection between the vagus nerve, gut microbiota, and the antidepressant effects of a novel compound called ineupatorolide B. This discovery not only broadens the scientific understanding of depression but also signals new directions for therapeutic interventions targeting the gut-brain axis.

Depression’s multifaceted nature has long challenged researchers and clinicians alike. Traditionally, treatments have focused on modulating neurotransmitters in the brain, such as serotonin and dopamine. However, increasing evidence reveals that the gut-brain axis — a bidirectional communication pathway linking the central nervous system and the gastrointestinal tract — plays a critical role in regulating mood and behavior. The vagus nerve acts as a central highway in this communication chain, transmitting signals between the gut microbiota and the brain. New data suggests that manipulating this neural conduit might be key to unlocking novel antidepressant mechanisms.

At the core of the study by Wang and colleagues lies ineupatorolide B, a bioactive compound isolated from natural sources with previously unexplored neuropsychiatric potential. Using a well-validated mouse model of depression, the researchers meticulously demonstrated that administration of ineupatorolide B amends depressive-like behaviors, an effect intricately linked to alterations in the gut microbial community. The compound’s antidepressant actions were shown to be dependent on an intact vagus nerve, underscoring the impossibility of fully dissociating gut-brain interactions from mood regulation.

To induce depressive symptoms in mice, the team employed chronic stress paradigms mimicking real-world psychological stressors. Behavioral assessments post-treatment revealed notable improvements in exploratory behavior and reduced signs of despair, pointing to the efficacy of ineupatorolide B. Subsequent gut microbiota analyses uncovered a significant shift in microbial diversity and composition following treatment, characterized by an enrichment of beneficial bacterial taxa previously associated with anti-inflammatory and neuroprotective functions.

The vagus nerve, often described as the “information superhighway” of the parasympathetic nervous system, emerged as the linchpin in this neuro-gastrointestinal axis. When the researchers surgically severed or pharmacologically inhibited the vagus nerve, the antidepressant benefits of ineupatorolide B were abolished. This pivotal finding confirms that gut microbiota alterations alone are insufficient and must be coupled with vagus-mediated signaling to exert mood-enhancing effects, highlighting a complex neuroimmune dialogue.

Delving deeper, molecular and immunohistochemical analyses revealed that ineupatorolide B impacts systemic and neural inflammatory pathways. The compound reduced expression of pro-inflammatory cytokines within the hippocampus, a brain region critically implicated in mood disorders, while simultaneously fostering neurogenesis and synaptic plasticity. These neurobiological enhancements offer plausible mechanistic explanations for the behavioral improvements observed and reinforce the notion that inflammation is intricately tied to depression’s pathophysiology.

Perhaps most intriguingly, the study unveiled a specific pattern of microbial metabolites altered by ineupatorolide B treatment. These metabolites are hypothesized to cross the gut-blood barrier and act on vagal afferent fibers, modulating neuronal excitability and neurotransmitter release. Such findings cultivate an emerging paradigm where microbial metabolites are not mere byproducts but active signaling molecules intricately shaping the neurochemical milieu of the brain.

The implications of these findings ripple far beyond basic science. In clinical settings, harnessing vagus-dependent pathways could revolutionize antidepressant therapies by focusing on microbiota modulation rather than conventional neurotransmitter-targeted drugs, many of which suffer from delayed onset and limited efficacy. This research provides a compelling preclinical rationale for developing compounds that modulate gut-brain interactions more precisely and with fewer adverse effects.

Moreover, the identification of ineupatorolide B as a bioactive agent extends the possibilities of phytochemical and natural product libraries as untapped reservoirs for neuropsychiatric drug discovery. While still in early stages, translational efforts can now investigate whether such compounds, alone or in synergy with probiotic treatments, can elicit robust therapeutic outcomes in humans suffering from depression and related disorders.

Future inquiries will need to delineate the precise molecular receptors on vagal afferents activated by microbial metabolites induced by ineupatorolide B, a vital step toward targeted drug design. Additionally, unraveling the longitudinal effects and safety profiles of modulating the gut-brain axis via this compound will be essential in moving toward clinical applications.

Beyond depression, these insights may have broader implications for other neuropsychiatric and neurodegenerative diseases also characterized by gut dysbiosis and neuroinflammation, such as anxiety, Parkinson’s disease, and multiple sclerosis. As the field of psychobiotics burgeons, the vagus nerve stands out as a promising therapeutic target whose modulation could recalibrate the neural circuits governing emotion, cognition, and behavior.

The integration of microbiology, neurobiology, and pharmacology showcased in this study epitomizes the power of interdisciplinary science to unlock novel therapeutic pathways. Wang and colleagues’ work thus represents a beacon in personalized medicine strategies aimed at mental health, a field urgently craving innovation as global depression rates continue to climb amid societal challenges.

In summary, the discovery that ineupatorolide B’s antidepressant efficacy is mediated by vagus nerve-dependent modulation of gut microbiota ushers in a transformative perspective on depression treatment. By bridging peripheral microbial ecosystems with central nervous system function via neural pathways, this research redefines our understanding of depression’s origins and therapeutic targets, inspiring the next generation of holistic and targeted interventions for mental health.

As the scientific community rallies around the gut-brain axis, studies such as this underscore the necessity of viewing depression through a systemic lens, acknowledging the profound interplay between the body and mind. This conceptual shift stands poised to not only improve treatment outcomes but also destigmatize mental illness by emphasizing its biological complexity.

Ultimately, as neuroscience continues to unravel the enigmatic connections between microbiota, neural circuits, and behavior, hopes rise for innovative treatments grounded in nature’s own chemical repertoire. Ineupatorolide B shines as a fascinating candidate at this frontier, exemplifying the promise held by gut-mediated neuromodulation in conquering depression’s global burden.

---

Subject of Research:
Vagus nerve-mediated antidepressant effects of ineupatorolide B through modulation of gut microbiota in a mouse depression model.

Article Title:
Vagus nerve–dependent antidepressant effects of ineupatorolide B via gut microbiota modulation in a mouse model of depression.

Article References:
Wang, S., Zhang, Y., Wu, N. et al. Vagus nerve–dependent antidepressant effects of ineupatorolide B via gut microbiota modulation in a mouse model of depression. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04127-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04127-x

In a groundbreaking advance poised to reshape how we approach brain health across the human lifespan, recent research reveals that integrating the principles of metaplasticity into therapeutic interventions can dramatically enhance their effectiveness. Metaplasticity, often described as the “plasticity of plasticity,” refers to the brain’s dynamic ability to regulate its own synaptic plasticity based on prior activity and environmental inputs. This emerging understanding promises to revolutionize strategies for cognitive enhancement and neurological rehabilitation, offering personalized and adaptive therapies that evolve with the individual’s brain state.

The concept of metaplasticity extends the traditional notion of neuroplasticity, emphasizing that synaptic changes are not static but modulated by previous experiences. This regulatory mechanism ensures that synaptic modifications occur within optimal ranges, preventing the neural circuits from becoming either too rigid or overly malleable. Recognizing this, scientists are now exploring interventions that do more than promote plasticity—they strategically prime the brain’s plastic potential to achieve sustained and balanced neural adaptability.

Life-course brain health is a complex interplay of genetic, environmental, and experiential factors that cumulatively influence neural function. Traditional interventions often apply a one-size-fits-all model, ignoring the fluctuating states of neural readiness and adaptation across developmental stages. By contrast, therapies informed by metaplasticity tailor their application according to the individual’s neurobiological context, potentially enhancing outcomes in cognitive development, neurorehabilitation after injury, and age-related cognitive decline.

The research underscores the importance of timing and context in brain health interventions. Synaptic plasticity is not merely about stimulating neurons but about doing so when they are optimally susceptible to change. This temporal precision is critical during sensitive periods in childhood and adolescence when the brain’s structure and function undergo rapid transformation. Incorporating metaplasticity principles means recognizing these windows of opportunity and adapting interventions to harness the brain’s highest potential for growth and recovery.

Moreover, metaplasticity offers intriguing insights into why certain neurological and psychiatric conditions manifest, persist, or respond variably to treatment. In disorders such as autism spectrum disorder, schizophrenia, and depression, dysregulation of plasticity mechanisms is increasingly implicated. Understanding how metaplasticity governs synaptic strength and flexibility not only facilitates more refined diagnostic frameworks but also guides innovative therapeutic designs that can recalibrate neural networks more effectively.

Neurorehabilitation strategies following traumatic brain injury or stroke stand to benefit immensely from a metaplasticity-informed approach. Current protocols focus heavily on repetitive stimulation or training, but without considering the brain’s shifting landscape of plasticity thresholds. By integrating metaplastic principles, clinicians can optimize the intensity and nature of rehabilitation exercises to coincide with periods when neuronal circuits are most adaptable, potentially accelerating recovery and improving functional outcomes.

This paradigm shift also extends into the realm of aging and neurodegenerative diseases. As brain plasticity declines with age, interventions designed to restore or boost neuroplastic capacity need to be sensitive to the evolving metaplastic state of neural circuits. Targeting these mechanisms might slow cognitive decline, improve memory retention, and enhance quality of life for older adults. Such interventions could include tailored cognitive training paradigms, pharmacological agents, or even non-invasive brain stimulation techniques employed with metaplastic timing considerations.

Critically, the application of metaplasticity in clinical settings demands a robust biomarker framework to assess brain state and plastic potential dynamically. Advances in neuroimaging and electrophysiological monitoring are instrumental in this regard, enabling real-time tracking of circuit responsiveness and guiding intervention adjustments. This precision medicine approach promises not only better therapeutic efficacy but also minimizes adverse effects associated with inappropriate stimulation.

As the scientific community deepens its understanding of metaplasticity, ethical considerations around intervention timing and intensity come into sharper focus. The prospect of manipulating brain plasticity across the lifespan raises questions about long-term consequences, individual variability, and the balance between enhancement and harm. Ongoing research must address these concerns through rigorous longitudinal studies and multidisciplinary dialogues involving neuroscience, bioethics, and patient advocacy.

Education systems may also harness knowledge on metaplasticity to optimize learning processes. By structuring curricula and educational environments that align with periods of heightened neural receptivity, educators can facilitate more effective skill acquisition and cognitive development. This integration of neuroscience and pedagogy represents a transformative step towards personalized learning experiences tailored to the brain’s natural rhythms of plasticity.

The public health implications are profound, as metaplasticity-guided interventions could democratize brain health strategies, making them more accessible and tailored beyond clinical populations. Community programs aimed at mental wellness, resilience building, and cognitive maintenance might incorporate metaplastic principles to maximize their impact, fostering healthier neural aging trajectories and buffering against stress-related neural degradation.

Future research efforts are focused on unraveling the molecular substrates that orchestrate metaplastic adjustments, including intracellular signaling pathways, neurotransmitter systems, and gene expression dynamics. These investigations hold promise for the development of novel pharmacotherapies that target metaplastic regulators, offering precise modulation of neural plasticity in disease states and healthy brains alike.

In conclusion, applying the burgeoning knowledge of metaplasticity marks a profound evolution in brain health interventions. This approach compels a reexamination of how neuroscientists and clinicians conceptualize brain adaptability, emphasizing a lifelong, context-dependent modulation of neuroplastic potential. As this paradigm gains traction, it sets the stage for more refined, effective, and ethically conscious strategies to optimize brain function from infancy through advanced age.

---

Subject of Research: Life-course brain health interventions and the role of metaplasticity in optimizing therapeutic outcomes.

Article Title: Life-course brain health intervention choices are improved by applying knowledge of metaplasticity.

Article References:
Scher, M.S. Life-course brain health intervention choices are improved by applying knowledge of metaplasticity. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05183-1

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05183-1

In a groundbreaking study shedding light on the molecular intricacies of arousal regulation, researchers from Pompeu Fabra University (UPF) and the Centre for Genomic Regulation (CRG) have unveiled the profound influence of neuronal microexons on behavioral states in zebrafish. This study elucidates how subtle alterations in these tiny genetic fragments can trigger hyperarousal—a state marked by heightened neural excitability and pronounced insomnia-like symptoms—which echoes the pathophysiological features observed in various neurodevelopmental disorders. The implications extend far beyond aquatic models, offering a window into the conserved mechanisms of arousal that potentially inform conditions such as autism spectrum disorder and schizophrenia in humans.

Arousal represents a fundamental neurophysiological process essential for survival, enabling organisms to respond to external and internal stimuli with appropriate behavioral and neural adaptations. This highly conserved mechanism across species ensures a meticulously balanced state, modulating responsiveness between lethargy and sensory hypersensitivity. Dysregulation of this balance manifests clinically as either diminished responsiveness or excessive wakefulness and sensory overload, typical hallmarks of stress and various neurodevelopmental pathologies.

Fundamental to this regulatory system is the diversity of proteins synthesized during development and adulthood through alternative splicing—a sophisticated post-transcriptional gene editing process. Alternative splicing enables the generation of multiple functionally distinct protein isoforms from a single gene, often mediated by the inclusion or exclusion of microexons. Microexons are exceptionally short exonic sequences within neuronal genes that profoundly influence protein function and neuronal circuit dynamics despite their minuscule size.

The investigative team employed zebrafish larvae, leveraging their optical transparency and genetic tractability to scrutinize the behavioral consequences of neural microexon misregulation. Larvae exhibiting abnormal microexon patterns demonstrated conspicuous hyperarousal behaviors including disrupted swim patterns and shortened sleep duration. “These larvae not only sleep less frequently but also take considerably longer to initiate sleep,” remarks first author Tahnee Mackensen. This behavioral hyperactivity parallels neural hyperexcitability, suggesting microexon regulation as a pivotal determinant of neurobehavioral states.

At the cellular signaling level, the researchers identified dysregulated cyclic adenosine monophosphate (cAMP) cascades as a key mediator of the observed hyperactive state. cAMP is a ubiquitous second messenger involved in modulating neuronal excitability and synaptic plasticity. The altered splicing of microexons modulates cAMP synthesis and degradation pathways, leading to an aberrant excitation of forebrain neurons in hyperaroused larvae. Notably, this altered cAMP signaling manifests as heightened cAMP-dependent protein kinase A (PKA) activity and subsequent phosphorylation of the transcription factor CREB, implicating the canonical cAMP-PKA-CREB pathway in the regulation of arousal.

The study’s pharmacological interventions underscore the centrality of cAMP regulation in arousal control. Application of cAMP inhibitors normalized the elevated neural activity and behavioral hyperarousal in mutant fish, whereas artificially elevating cAMP in wild-type fish recapitulated the hyperactive phenotype. This bidirectional modulation fortifies the concept that neuronal cAMP levels function as a ‘thermostat’ for arousal states, fine-tuning neuronal excitability and behavioral responsiveness.

Beyond the immediate findings in zebrafish, this research builds upon prior observations in drosophila models demonstrating that microexon disruption similarly impairs sleep and elevates arousal. “The parallel between species indicates an evolutionarily conserved arousal mechanism,” explains Manuel Irimia, senior author. This conservation implies that microexon misregulation, while mechanistically nuanced, may contribute to the neuropsychiatric symptomatology observed in mammals, including humans.

Human neurological disorders such as autism and schizophrenia are often accompanied by sleep disruption and sensory processing anomalies attributed, in part, to aberrant microexon splicing. While microexon alterations are unlikely to be sole causative factors, they may exacerbate or modulate disease phenotypes by disturbing neural excitability homeostasis. These insights prompt a reevaluation of therapeutic strategies aimed at restoring microexon splicing fidelity or modulating cAMP signaling pathways to alleviate neurodevelopmental symptomatology.

Moreover, the link between this microexon-cAMP pathway and mood disorders such as anxiety and depression opens compelling avenues for future research. The cAMP-PKA-CREB axis has well-documented roles in synaptic plasticity and mood regulation, suggesting that microexon-associated dysregulation could contribute to broader neuropsychiatric conditions. “This discovery might just scratch the surface of a complex regulatory network influencing brain function,” notes Mackensen.

The transparency and genetic accessibility of the zebrafish model provided unparalleled opportunities to visualize and quantify internal states through behavioral readouts. Advanced imaging of larval swimming patterns and direct measurement of neurochemical parameters furnished robust correlative evidence linking genetic alterations to functional outcomes. These technical advancements highlight the integrative power of model organisms in neuroscience.

Importantly, this research received support from an array of prestigious funding bodies, including the Horizon 2020 Framework Programme, the Marie Sklodowska-Curie Actions, and the Wellcome Trust, emphasizing the global significance and collaborative nature of this work. The study’s publication in Science Advances confirms its high impact and relevance to the scientific community.

As the team pursues translational studies, the prospect of correcting arousal imbalances by manipulating cAMP pathways or restoring microexon expression presents a promising frontier. This is especially critical given that aberrant arousal and sleep disturbances profoundly impair quality of life in neurodevelopmental disorders. The findings pave the way for multidisciplinary approaches integrating molecular genetics, neurobiology, and pharmacology to develop targeted interventions.

In summation, the identification of neuronal microexons as key modulators of arousal states via the cAMP-PKA-CREB pathway in zebrafish represents a seminal advance in our understanding of the molecular substrates governing complex behavioral phenotypes. This research not only deciphers fundamental biological mechanisms but also holds translational potential to inform therapeutic avenues for neuropsychiatric conditions marked by disrupted arousal and sleep.

---

Subject of Research: Animals

Article Title: Neuronal microexons modulate arousal via the cAMP-PKA-CREB pathway in zebrafish

News Publication Date: 19-Jun-2026

Web References: 10.1126/sciadv.ady8291

Image Credits: UPF – CRG

Keywords: Exons, Gene splicing, Developmental neuroscience, Anxiety, Sleep disorders, cAMP signaling, Zebrafish

Apple’s grip on iPhone app distribution is loosening in another major market: Brazil.

German technology giant Bosch settled a case with the US Department of Commerce for supplying $72 million-worth of sensor products and software subject to export restrictions to Huawei.

The products falling foul of US rules were Micro-Electro-Mechanical Systems (MEMS) sensors used in smartphones, wearables and vehicles, along with automotive software.

Announcing the $36.2 million settlement, the US department’s Bureau of Industry and Security (BIS) noted Bosch had disclosed the information itself and cooperated with the subsequent proceedings.

BIS explained the products shipped to Huawei or affiliates were covered by the Foreign Direct Product Rule, part of Export Administration Regulations (EAR) restricting the supply of some goods made using specific technology of US origin without a licence.

Shipments found to break the rules were made between 16 September 2020 and 26 September 2024.

Alongside the fine, Bosch must give up profits made as a result of the transactions.  

BIS assistant secretary of commerce for export enforcement David Peters said the company had “several opportunities to avoid these violations had they exercised the increased vigilance BIS has repeatedly said it expects of companies whose transactions are governed by the EAR”.

“Today’s action should serve as a warning to embrace compliance and as an example of the benefits of voluntary self-disclosure.”

The post Huawei shipments cost Bosch $36M appeared first on Mobile World Live.

Laminin subunit beta 3 (LAMB3) has emerged as a critical player in the molecular landscape of cancer, yet its precise role in gastric cancer (GC) progression has remained elusive until now. A groundbreaking study published in the British Journal of Cancer unravels the intricate mechanisms by which LAMB3 exacerbates malignancy in GC, shedding light on a novel molecular axis that could revolutionize therapeutic approaches. This research uncovers how LAMB3 orchestrates the sustained activation of the PI3K-Akt pathway—one of the most prominent signaling routes involved in tumor growth and survival—through targeted degradation of PHLPP2 mRNA mediated by the RNA-binding protein SAMD4A.

Gastric cancer continues to rank among the leading causes of cancer mortality worldwide, with its complex molecular underpinnings posing a significant challenge to effective treatment. Despite advances in understanding various oncogenic drivers, the involvement of extracellular matrix components like LAMB3 has been underappreciated. Laminins, as glycoproteins critical for basement membrane structure and signaling, influence cell adhesion, migration, and differentiation. The aberrant overexpression of LAMB3 in various cancers hinted at its potential role in tumor aggressiveness, yet the mechanistic details remained uncharted until the present study’s in-depth molecular analyses.

The authors employed a comprehensive experimental framework combining transcriptomic analysis, RNA immunoprecipitation, and functional assays in gastric cancer cell lines and murine xenograft models. They demonstrated that LAMB3 upregulation correlates with increased GC cell proliferation, invasion, and metastatic potential. More strikingly, LAMB3 was found to exert these oncogenic effects by destabilizing PHLPP2 mRNA, a known tumor suppressor that negatively regulates the PI3K-Akt signaling axis. This discovery positions LAMB3 as a pivotal regulator of intracellular signaling networks that propel oncogenesis.

At the heart of this regulatory pathway lies SAMD4A, an RNA-binding protein previously unlinked to gastric cancer pathophysiology. The study reveals that LAMB3 enhances the interaction between SAMD4A and PHLPP2 mRNA, promoting its degradation through post-transcriptional mechanisms. This SAMD4A-mediated mRNA decay leads to a marked reduction in PHLPP2 protein levels, unleashing hyperactivation of the PI3K-Akt pathway. Such persistent signaling drives uncontrolled cellular proliferation and survival, hallmark features of aggressive cancer phenotypes.

Mechanistically, the suppression of PHLPP2 removes a vital check on Akt phosphorylation, facilitating an unchecked flow of pro-survival signals inside the cancer cells. The PI3K-Akt pathway modulates diverse cellular functions, including metabolism, apoptosis resistance, and cell cycle progression. By unraveling this axis, the study prominently positions LAMB3—and its downstream effectors—as promising biomarkers and therapeutic targets in GC, where tailored interventions are urgently needed.

Notably, the research team extended their findings to patient-derived GC tissues, confirming that elevated LAMB3 expression significantly correlates with poor prognosis and advanced disease stages. The clinical relevance strengthens the translational potential of targeting the LAMB3-SAMD4A-PHLPP2 axis, suggesting that disrupting this molecular cascade might curtail tumor progression and improve patient outcomes.

Beyond the intrinsic mechanistic insights, the study raises intriguing possibilities for drug development. Small molecules or RNA-based therapeutics that inhibit LAMB3 expression or interfere with SAMD4A’s binding to PHLPP2 mRNA could restore tumor suppressor function and dampen aberrant signaling. Given the centrality of PI3K-Akt in many cancers, such interventions might have broad applicability beyond just gastric malignancies, positioning this discovery at the forefront of precision oncology.

Moreover, the findings provoke a reevaluation of how extracellular matrix components, traditionally viewed as structural elements, actively participate in intracellular oncogenic signaling. The delineation of LAMB3’s role in manipulating RNA stability via SAMD4A opens a relatively unexplored frontier in cancer biology: the crosstalk between the extracellular milieu and post-transcriptional gene regulation. This interplay hints at a complex regulatory network that underpins cancer cells’ adaptability and survival in hostile microenvironments.

The study also highlights the importance of integrating multi-omics data to dissect the sophisticated molecular interactions governing cancer progression. Through the use of advanced RNA immunoprecipitation and sequencing techniques, the researchers mapped the dynamic interactions between RNA-binding proteins and specific mRNA targets, elucidating a critical post-transcriptional regulatory node controlled by LAMB3. Such approaches exemplify the power of cutting-edge molecular biology tools in unveiling hidden layers of cancer biology.

Future research is poised to explore whether similar mechanisms operate in other epithelial cancers where LAMB3 is dysregulated. Comparative analyses across tumor types could validate the universality of this pathway, potentially expanding the clinical impact of these findings. Furthermore, understanding how LAMB3 expression itself is regulated, including potential epigenetic and transcriptional modulators, could unveil additional therapeutic leverage points.

Identifying effective inhibitors of the LAMB3-SAMD4A interaction stands as an exciting therapeutic frontier. While challenging, the small interface between RNA-binding proteins and target mRNAs offers a unique opportunity to develop molecules with high specificity and minimal off-target effects. Collaboration between molecular biologists, chemists, and clinical researchers will be critical to translate these molecular insights into viable therapies.

In summary, this landmark study elucidates a novel molecular mechanism whereby LAMB3 promotes gastric cancer progression through the SAMD4A-mediated degradation of PHLPP2 mRNA, sustaining PI3K-Akt signaling. By connecting extracellular matrix components to post-transcriptional gene regulation and oncogenic signaling, it not only advances fundamental understanding of gastric cancer biology but also charts a promising path toward innovative treatment strategies. As gastric cancer continues to exact a heavy toll worldwide, such pioneering research offers new hope for improved diagnosis, prognosis, and therapeutic intervention.

The implications of this discovery extend beyond the realm of gastric cancer, potentially influencing broader fields of oncology and RNA biology. As the scientific community delves deeper into the non-canonical functions of extracellular proteins and RNA-binding factors, the intricate tapestry of cancer’s molecular underpinnings becomes progressively clearer. The LAMB3-SAMD4A-PHLPP2 axis may well become a focal point in the ongoing quest to outmaneuver cancer at its molecular roots.

With continued investment in translational research and clinical trials inspired by these findings, the next decade could herald significant breakthroughs in managing gastric cancer and related malignancies. This study stands as a testament to the power of multidisciplinary approaches in tackling one of humanity’s most formidable health challenges, combining molecular precision with clinical urgency to pave the way toward a future where gastric cancer progression can be effectively stalled or reversed.

---

Subject of Research: Molecular mechanisms driving gastric cancer malignancy involving LAMB3-mediated regulation of mRNA stability and signaling pathways.

Article Title: LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation.

Article References:
Guo, J., Cai, F., Zhang, M. et al. LAMB3 drives gastric cancer progression through SAMD4A-mediated degradation of PHLPP2 mRNA leading to sustained PI3K-Akt activation. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03496-w

Image Credits: AI Generated

DOI: 2026-06-17

In a groundbreaking study published in Nature Communications, scientists have unveiled how a mitochondrial protein known as OPA3 plays a pivotal role in sustaining cardiac function by regulating calcium handling in male mice. This discovery sheds new light on the intricate cellular mechanisms that underpin heart performance and opens up promising avenues for treating cardiovascular diseases, which remain a leading cause of mortality worldwide. The findings emphasize the critical interplay between mitochondrial dynamics and calcium signaling within cardiac muscle cells, providing a fresh perspective on how cellular energy production influences heart health.

The heart’s ability to maintain rhythmic and efficient contractions is fundamentally dependent on the precise regulation of intracellular calcium levels. Calcium ions serve as essential second messengers in cardiac myocytes, triggering contraction through complex signaling cascades. However, the interplay between calcium dynamics and mitochondrial proteins, especially those involved in mitochondrial morphology and function, has remained elusive until now. The current study identifies the mitochondrial protein OPA3 as a key modulator in this regulatory network, maintaining both mitochondrial integrity and calcium homeostasis crucial for cardiac contractility.

OPA3 is traditionally recognized for its role in maintaining mitochondrial morphology, particularly in mitochondrial fission and fusion processes. These processes are vital for preserving the mitochondrial network’s dynamic nature, which is essential for cellular energy metabolism. Mitochondria not only produce ATP but also buffer intracellular calcium, thereby influencing calcium signaling within cardiac cells. By elucidating how OPA3 influences calcium handling, researchers have bridged an important gap between mitochondrial structural proteins and the functional output of cardiac cells.

Experimental models using male mice engineered for OPA3 depletion revealed significant impairments in cardiac function, demonstrating that loss of OPA3 disrupts calcium cycling in cardiac myocytes. Impaired calcium handling directly correlates with diminished contractile force and defective cardiac output. This suggests that OPA3’s influence extends beyond structural maintenance and into functional regulation of calcium channels or transporters. The dysregulation of such a critical ion pathway can lead to arrhythmias and cardiac failure, underscoring the potential clinical significance of these findings.

At the molecular level, the study highlights that OPA3 affects the expression and activity of key calcium regulators including the sarcoplasmic reticulum Ca2+ ATPase (SERCA) and ryanodine receptors (RyR). These proteins govern calcium reuptake and release in cardiac cells, orchestrating contraction and relaxation cycles. Through advanced imaging and electrophysiological techniques, the research team demonstrated that OPA3 deficiency impairs SERCA function and causes aberrant RyR-mediated calcium leak, leading to calcium overload or deficits. Such pathophysiological alterations are known contributors to cardiac hypertrophy and heart failure in humans.

The investigation also explores the bioenergetic consequences of OPA3 modulation. Mitochondrial bioenergetics in cardiac muscle cells are highly tuned to meet the energy demands of continuous contractions. OPA3 deficiency was found to compromise mitochondrial ATP production by disrupting inner membrane potential and electron transport chain efficiency. These mitochondrial defects culminate in inadequate energy supply for calcium pumps and ion exchangers, further exacerbating contractile dysfunction. This uncovers a feedback loop where structural mitochondrial proteins like OPA3 indirectly regulate calcium handling by maintaining energetic homeostasis.

A remarkable aspect of the study lies in its use of state-of-the-art imaging techniques such as live-cell confocal microscopy and super-resolution electron microscopy, which revealed morphological abnormalities in mitochondria lacking OPA3. Fragmented and swollen mitochondria with disrupted cristae architecture were prevalent in OPA3-deficient cardiomyocytes. These structural derangements are likely responsible for the observed bioenergetic failures and altered calcium buffering capacity, collectively impairing the cardiomyocyte’s functional integrity.

Furthermore, the team utilized optogenetics-based calcium sensors to monitor real-time calcium flux in isolated cardiomyocytes, providing unprecedented insight into how OPA3 influences calcium transients during excitation-contraction coupling. Data revealed that OPA3 loss leads to prolonged calcium decay time and increased diastolic calcium levels, conditions that predispose cardiac cells to arrhythmic events and contractile inefficiency. These calcium handling anomalies could explain the pathophysiology of certain forms of cardiomyopathy linked to mitochondrial dysfunction.

Importantly, the study addresses the potential sex-specific roles of OPA3, noting that experiments were conducted exclusively in male mice to control for hormonal influences on cardiac physiology. This raises intriguing questions about whether OPA3 functions similarly in female models and whether sex hormones modulate its expression or activity. Such considerations are critical as sex differences in cardiovascular disease outcomes are well-documented, emphasizing the need for further research in this domain.

The translational implications of these findings are profound. Therapeutic strategies aimed at restoring or enhancing OPA3 function could stabilize mitochondrial morphology and bioenergetics, thereby normalizing calcium handling and improving cardiac contractility. Such interventions might hold promise for treating heart failure syndromes characterized by mitochondrial and calcium dysregulation. Moreover, identifying small molecules or gene therapies targeting OPA3 pathways might complement existing treatments that primarily focus on calcium channels but neglect mitochondrial contributions.

Beyond the heart, the role of OPA3 in mitochondrial dynamics suggests potential relevance in other tissues with high energetic demand, such as skeletal muscle and the brain. Defects in mitochondrial morphology and calcium handling have been implicated in neurodegenerative diseases and metabolic disorders. Thus, understanding OPA3’s function could have broad implications in diverse biomedical fields, making it a protein of significant interest in physiology and pathophysiology.

This study also raises several compelling scientific questions for future research. How does OPA3 interact with other mitochondrial fission and fusion proteins, such as OPA1, MFN1/2, and DRP1, in regulating calcium signaling? What are the upstream regulators of OPA3 expression in cardiac tissue under physiological and pathological conditions? Additionally, can OPA3 modulation reverse established cardiac dysfunction or is it mainly preventive? Addressing these queries will deepen our understanding of cardiac mitochondrial biology and pave the way for novel therapeutic innovations.

Addressing cardiac diseases from a mitochondrial perspective represents a paradigm shift in cardiovascular medicine. Historically, calcium handling has been studied primarily through its direct regulators, but this research highlights the necessity of considering mitochondrial proteins like OPA3 as integral components of intracellular calcium homeostasis. This refined viewpoint may revolutionize how clinicians and scientists approach diagnosis, prognosis, and treatment of cardiac ailments.

In conclusion, the identification of mitochondrial protein OPA3 as a fundamental regulator of cardiac calcium handling marks a significant advance in cardiovascular biology. By elucidating the link between mitochondrial morphology, energy metabolism, and calcium signaling, this work provides critical insights into the molecular basis of cardiac function and dysfunction. It offers hope for innovative interventions that could alleviate the burden of heart disease, fostering improved patient outcomes and advancing the frontier of precision medicine in cardiology.

Subject of Research:
Mitochondrial protein OPA3 and its role in cardiac function via regulation of intracellular calcium handling mechanisms.

Article Title:
Mitochondrial protein OPA3 sustains cardiac function by regulating calcium handling in male mice.

Article References:
Geng, N., Chen, T., Li, H. et al. Mitochondrial protein OPA3 sustains cardiac function by regulating calcium handling in male mice. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73991-4

Image Credits: AI Generated